Gene
ATR
ATR is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (6), Actionable biomarkers (5), Trial mentions (123), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ATR. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 14 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 6 of 8,738 | 0.07% | not measured | |
| 2025 | 8 of 8,875 | 0.09% | not measured | |
| 2024 | 7 of 8,597 | 0.08% | not measured | |
| 2023 | 10 of 8,275 | 0.12% | 31 of 11,460 | 0.27% |
| 2022 | 18 of 8,285 | 0.22% | 32 of 13,598 | 0.24% |
| 2021 | 16 of 8,692 | 0.18% | 35 of 15,045 | 0.23% |
| 2020 | 15 of 7,640 | 0.20% | 36 of 14,459 | 0.25% |
| 2019 | 11 of 7,300 | 0.15% | 22 of 12,159 | 0.18% |
| 2018 | 8 of 6,927 | 0.12% | 24 of 11,854 | 0.20% |
| 2017 | 5 of 6,558 | 0.08% | 17 of 11,595 | 0.15% |
Showing 10 of 37 years.
Assay-provider ledger (6)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Life Technologies | Reagent supplier | Clinical validation | 1 | August 26, 2025 |
| QIAGEN | Reagent supplier | Clinical validation | 1 | August 26, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 1 | August 26, 2025 |
| New Amsterdam Genomics, Inc. | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 01, 2020 |
| Frederick National Laboratory for Cancer Research | Not a company | Clinical validationAnalytical validation | 1 | August 01, 2016 |
Showing 5 of 6 assay-provider companies.
Actionable biomarkers (5)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ATR oncogenic mutation | Temozolomide | response-associated | glioma | Cancer Genome Interpreter |
| ATR deletion | OLAPARIB | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
| ATR oncogenic mutation | OLAPARIB | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
| ATR deletion | OLAPARIB | response-associated | No disease recorded | Cancer Genome Interpreter |
| ATR oncogenic mutation | OLAPARIB | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (123)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03375307 | Trial eligibility (AACT) |
| NCT07197593 | Trial eligibility (AACT) |
| NCT02630199 | Trial eligibility (AACT) |
| NCT05691491 | Trial eligibility (AACT) |
| NCT05536128 | Trial eligibility (AACT) |
Showing 5 of 123 trial mentions.
Target-disease associations (410)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 410 associations.
Vendor sourcing (398)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Stop-ga... | View ClinVar record SCV007608781.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001157171.6 |
| Aarhus University Hospital | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Patients who have not followed the regime at AUH (e.g. terminated use of the ROM- walker prematurely or similar) * Bilateral ATR or rupture of the oppos... | View trial NCT05614908 |
| Aarhus University Hospital | Trial sponsor | Mentioned in trial textTrial free-text mention | ATR | View trial NCT05614908 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
Showing 5 of 398 sourcing records.
Trial-cited literature (309)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | JCO precision oncology | 2025 | 9 |
| Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). | Cancer chemotherapy and pharmacology | 2025 | 9 |
| Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313). | The oncologist | 2025 | 1 |
| Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study. | Investigational new drugs | 2025 | 0 |
| NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer. | The oncologist | 2025 | 0 |
Showing 5 of 309 papers.
Protein variant mentions (93)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1009T | 1 | 2015 | PMID 25741868 |
| p.A218S | 1 | 2015 | PMID 25741868 |
| p.C128W | 1 | 2015 | PMID 25741868 |
| p.C1354S | 1 | 2015 | PMID 25741868 |
| p.C1858R | 1 | 2015 | PMID 25741868 |
Showing 5 of 93 variants.
Literature-extracted relations (26)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CISPLATIN | Chemical | associate |
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. | 2021 |
| GEMCITABINE | Chemical | associate |
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. | 2021 |
| GEMCITABINE | Chemical | associate |
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. | 2020 |
| TOPOTECAN | Chemical | associate |
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. | 2018 |
| Trabectedin | Chemical | associate |
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. | 2016 |
Showing 5 of 26 relation assertions.
Organizations publishing (358)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 20 | 2011 to 2025 |
| Harvard Medical School | Academic | 19 | 2009 to 2024 |
| Dana-Farber Cancer Institute | Other | 18 | 2009 to 2024 |
| Mayo Clinic | Hospital | 15 | 2012 to 2024 |
| The University of Texas System | Academic | 15 | 2008 to 2025 |
Showing 5 of 358 organizations.
Where ATR appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- nervous system disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
353 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.